UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 170

Sortiert nach

Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders

Frontiers in psychiatry, 2019-05, Vol.10, p.286-286

2019

Link zum Volltext

Verfügbarkeit prüfen

The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy

CNS drugs, 2019-06, Vol.33 (6), p.539-547

2019

Link zum Volltext

Verfügbarkeit prüfen

Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study

Translational psychiatry, 2021-08, Vol.11 (1), p.422-422, Article 422

2021

Link zum Volltext

Verfügbarkeit prüfen

Exploring Zentangle as a virtual mindfulness-based art intervention for people with serious mental illness

Frontiers in psychiatry, 2023-11, Vol.14, p.1260937-1260937

2023

Link zum Volltext

Verfügbarkeit prüfen

The impact of COVID-19 on individuals living with serious mental illness

Schizophrenia research, 2020-08, Vol.222, p.3-5

2020

Link zum Volltext

Verfügbarkeit prüfen

A Multi-Performance Reliability Evaluation Approach Based on the Surrogate Model with Cluster Mixing Weight

Applied sciences, 2024-07, Vol.14 (13), p.5813

2024

Link zum Volltext

Verfügbarkeit prüfen

Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia

European archives of psychiatry and clinical neuroscience, 2022-06, Vol.272 (4), p.633-642

2022

Link zum Volltext

Verfügbarkeit prüfen

Altered resting-state intra- and inter- network functional connectivity in patients with persistent somatoform pain disorder

PloS one, 2017-04, Vol.12 (4), p.e0176494-e0176494

2017

Link zum Volltext

Verfügbarkeit prüfen

Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia

Psychopharmacology, 2014, Vol.231 (2), p.319-325

2014

Link zum Volltext

Verfügbarkeit prüfen

Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment

Schizophrenia research, 2016-04, Vol.172 (1), p.1-8

2016

Link zum Volltext

Verfügbarkeit prüfen

Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight

Schizophrenia research, 2013-10, Vol.150 (1), p.269-273

2013

Link zum Volltext

Verfügbarkeit prüfen

Hippocampal and orbital inferior frontal gray matter volume abnormalities and cognitive deficit in treatment-naive, first-episode patients with schizophrenia

Schizophrenia research, 2014-02, Vol.152 (2), p.339-343

2014

Link zum Volltext

Verfügbarkeit prüfen

Activation of Th17 cells in drug naïve, first episode schizophrenia

Progress in neuro-psychopharmacology & biological psychiatry, 2014-06, Vol.51, p.78-82

2014

Link zum Volltext

Verfügbarkeit prüfen

The Role of Butyric Acid in Treatment Response in Drug-Naïve First Episode Schizophrenia

Frontiers in psychiatry, 2021-08, Vol.12, p.724664-724664

2021

Link zum Volltext

Verfügbarkeit prüfen

A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism

Schizophrenia research, 2014-11, Vol.159 (2), p.395-403

2014

Link zum Volltext

Verfügbarkeit prüfen

Duration of untreated psychosis is associated with temporal and occipitotemporal gray matter volume decrease in treatment naïve schizophrenia

PloS one, 2013-12, Vol.8 (12), p.e83679-e83679

2013

Link zum Volltext

Verfügbarkeit prüfen

Reduced Brain Activity in the Right Putamen as an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia

Frontiers in psychiatry, 2019-10, Vol.10, p.741-741

2019

Link zum Volltext

Verfügbarkeit prüfen

Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia

Psychiatry research, 2007-01, Vol.149 (1), p.267-271

2007

Link zum Volltext

Verfügbarkeit prüfen

Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia

Schizophrenia research, 2014-10, Vol.159 (1), p.51-55

2014

Link zum Volltext

Verfügbarkeit prüfen

Decreased cortical thickness in drug naïve first episode schizophrenia: In relation to serum levels of BDNF

Journal of psychiatric research, 2015-01, Vol.60, p.22-28

2015

Link zum Volltext

Verfügbarkeit prüfen

Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: A study of drug naive, first-episode schizophrenia patients and unaffected siblings

Schizophrenia research, 2014-10, Vol.159 (1), p.43-50

2014

Link zum Volltext

Verfügbarkeit prüfen

Decreased Functional Connectivity of Insular Cortex in Drug Naïve First Episode Schizophrenia: In Relation to Symptom Severity

PloS one, 2017-01, Vol.12 (1), p.e0167242-e0167242

2017

Link zum Volltext

Verfügbarkeit prüfen

Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia

Neuropsychiatric disease and treatment, 2017-01, Vol.13, p.397-406

2017

Link zum Volltext

Verfügbarkeit prüfen

Insulin Resistance and Oxidative Stress: In Relation to Cognitive Function and Psychopathology in Drug-Naïve, First-Episode Drug-Free Schizophrenia

Frontiers in psychiatry, 2020-11, Vol.11, p.537280-537280

2020

Link zum Volltext

Verfügbarkeit prüfen

APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia

PloS one, 2014-04, Vol.9 (4), p.e93902

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(164)
Mit Volltextzugriff
(157)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(135)
Life Sciences & Biomedicine
(112)
Psychiatry
(97)
Schizophrenia
(85)
Humans
(81)
Male
(65)
Female
(63)
Adult
(56)
Schizophrenia - Drug Therapy
(35)
Middle Aged
(34)
Biological And Medical Sciences
(33)
Medical Sciences
(31)
Young Adult
(31)
Adult And Adolescent Clinical Studies
(28)
Psychology. Psychoanalysis. Psychiatry
(28)
Psychopathology. Psychiatry
(28)
Psychoses
(28)
Adolescent
(24)
Antipsychotic Agents - Therapeutic Use
(24)
Pharmacology & Pharmacy
(23)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders

The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy

Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study

Exploring Zentangle as a virtual mindfulness-based art intervention for people with serious mental illness

The impact of COVID-19 on individuals living with serious mental illness

A Multi-Performance Reliability Evaluation Approach Based on the Surrogate Model with Cluster Mixing Weight

Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia

Altered resting-state intra- and inter- network functional connectivity in patients with persistent somatoform pain disorder

Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia

Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment

Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight

Hippocampal and orbital inferior frontal gray matter volume abnormalities and cognitive deficit in treatment-naive, first-episode patients with schizophrenia

Activation of Th17 cells in drug naïve, first episode schizophrenia

The Role of Butyric Acid in Treatment Response in Drug-Naïve First Episode Schizophrenia

A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism

Duration of untreated psychosis is associated with temporal and occipitotemporal gray matter volume decrease in treatment naïve schizophrenia

Reduced Brain Activity in the Right Putamen as an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia

Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia

Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia

Decreased cortical thickness in drug naïve first episode schizophrenia: In relation to serum levels of BDNF

Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: A study of drug naive, first-episode schizophrenia patients and unaffected siblings

Decreased Functional Connectivity of Insular Cortex in Drug Naïve First Episode Schizophrenia: In Relation to Symptom Severity

Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia

Insulin Resistance and Oxidative Stress: In Relation to Cognitive Function and Psychopathology in Drug-Naïve, First-Episode Drug-Free Schizophrenia

APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia

Suchergebnisse filtern